Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial.
8th AJCC
Breast cancer
HER2-positive
Prognostic stage
Trastuzumab
Journal
BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723
Informations de publication
Date de publication:
21 11 2019
21 11 2019
Historique:
received:
25
07
2019
accepted:
04
10
2019
entrez:
22
11
2019
pubmed:
22
11
2019
medline:
15
4
2020
Statut:
epublish
Résumé
The 8th edition of the American Joint Committee on Cancer (AJCC) staging has introduced prognostic stage based on anatomic stage combined with biologic factors. We aimed to validate the prognostic stage in HER2-positive breast cancer patients enrolled in the ShortHER trial. The ShortHER trial randomized 1253 HER2-positive patients to 9 weeks or 1 year of adjuvant trastuzumab combined with chemotherapy. Patients were classified according to the anatomic and the prognostic stage. Distant disease-free survival (DDFS) was calculated from randomization to distant relapse or death. A total of 1244 patients were included. Compared to anatomic stage, the prognostic stage downstaged 41.6% (n = 517) of patients to a more favorable stage category. Five-year DDFS based on anatomic stage was as follows: IA 96.6%, IB 94.1%, IIA 92.4%, IIB 87.3%, IIIA 81.3%, IIIC 70.5% (P < 0.001). Five-year DDFS according to prognostic stage was as follows: IA 95.7%, IB 91.4%, IIA 86.9%, IIB 85.0%, IIIA 77.6%, IIIC 67.7% (P < 0.001). The C index was similar (0.69209 and 0.69249, P = 0.975). Within anatomic stage I, the outcome was similar for patients treated with 9 weeks or 1 year trastuzumab (5-year DDFS 96.2% and 96.6%, P = 0.856). Within prognostic stage I, the outcome was numerically worse for patients treated with 9 weeks trastuzumab (5-year DDFS 93.7% and 96.3%, P = 0.080). The prognostic stage downstaged 41.6% of patients, while maintaining a similar prognostic performance as the anatomic stage. The prognostic stage is valuable in counseling patients and may serve as reference for a clinical trial design. Our data do not support prognostic stage as guidance to de-escalate treatment. EUDRACT number: 2007-004326-25; NCI ClinicalTrials.gov number: NCT00629278.
Sections du résumé
BACKGROUND
The 8th edition of the American Joint Committee on Cancer (AJCC) staging has introduced prognostic stage based on anatomic stage combined with biologic factors. We aimed to validate the prognostic stage in HER2-positive breast cancer patients enrolled in the ShortHER trial.
METHODS
The ShortHER trial randomized 1253 HER2-positive patients to 9 weeks or 1 year of adjuvant trastuzumab combined with chemotherapy. Patients were classified according to the anatomic and the prognostic stage. Distant disease-free survival (DDFS) was calculated from randomization to distant relapse or death.
RESULTS
A total of 1244 patients were included. Compared to anatomic stage, the prognostic stage downstaged 41.6% (n = 517) of patients to a more favorable stage category. Five-year DDFS based on anatomic stage was as follows: IA 96.6%, IB 94.1%, IIA 92.4%, IIB 87.3%, IIIA 81.3%, IIIC 70.5% (P < 0.001). Five-year DDFS according to prognostic stage was as follows: IA 95.7%, IB 91.4%, IIA 86.9%, IIB 85.0%, IIIA 77.6%, IIIC 67.7% (P < 0.001). The C index was similar (0.69209 and 0.69249, P = 0.975). Within anatomic stage I, the outcome was similar for patients treated with 9 weeks or 1 year trastuzumab (5-year DDFS 96.2% and 96.6%, P = 0.856). Within prognostic stage I, the outcome was numerically worse for patients treated with 9 weeks trastuzumab (5-year DDFS 93.7% and 96.3%, P = 0.080).
CONCLUSIONS
The prognostic stage downstaged 41.6% of patients, while maintaining a similar prognostic performance as the anatomic stage. The prognostic stage is valuable in counseling patients and may serve as reference for a clinical trial design. Our data do not support prognostic stage as guidance to de-escalate treatment.
TRIAL REGISTRATION
EUDRACT number: 2007-004326-25; NCI ClinicalTrials.gov number: NCT00629278.
Identifiants
pubmed: 31747948
doi: 10.1186/s12916-019-1445-z
pii: 10.1186/s12916-019-1445-z
pmc: PMC6868696
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
Trastuzumab
P188ANX8CK
Banques de données
ClinicalTrials.gov
['NCT00629278']
EudraCT
['2007-004326-25']
Types de publication
Clinical Trial, Phase III
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Validation Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
207Références
Eur J Surg Oncol. 2019 Oct;45(10):1817-1820
pubmed: 30926158
J Clin Oncol. 2019 Aug 1;37(22):1868-1875
pubmed: 30939096
J Breast Cancer. 2018 Jun;21(2):173-181
pubmed: 29963113
Ann Oncol. 2018 Dec 1;29(12):2273-2274
pubmed: 30357308
Oncologist. 2017 Nov;22(11):1292-1300
pubmed: 28592619
Virchows Arch. 2019 Feb;474(2):193-200
pubmed: 30474738
J Cancer Res Clin Oncol. 2016 Mar;142(3):669-78
pubmed: 26531187
Chin J Cancer Res. 2017 Aug;29(4):351-360
pubmed: 28947867
Cochrane Database Syst Rev. 2012 Apr 18;(4):CD006243
pubmed: 22513938
Anticancer Res. 2017 Aug;37(8):4615-4621
pubmed: 28739761
Breast Cancer Res Treat. 2018 Feb;168(1):269-275
pubmed: 29143220
Ann Oncol. 2018 Dec 1;29(12):2328-2333
pubmed: 30219886
JAMA Oncol. 2018 Feb 1;4(2):203-209
pubmed: 29222540
Am Soc Clin Oncol Educ Book. 2018 May 23;38:38-46
pubmed: 30231409
Breast Cancer Res Treat. 2018 Oct;171(3):737-745
pubmed: 29931426
CA Cancer J Clin. 2017 Jul 8;67(4):290-303
pubmed: 28294295
Ann Surg. 2018 Oct 11;:
pubmed: 30312199
Cancer Manag Res. 2019 Feb 13;11:1433-1442
pubmed: 30863154
World J Oncol. 2017 Jun;8(3):71-75
pubmed: 29147438
Ann Oncol. 2017 Aug 1;28(8):1700-1712
pubmed: 28838210
Am Soc Clin Oncol Educ Book. 2018 May 23;38:457-467
pubmed: 30231399
Breast Cancer Res Treat. 2018 Jun;169(2):257-266
pubmed: 29388016
Curr Opin Oncol. 2019 Jan;31(1):35-42
pubmed: 30325338
Future Oncol. 2019 Feb;15(4):391-400
pubmed: 30620221
Clin Breast Cancer. 2018 Dec;18(6):e1347-e1352
pubmed: 30078612
Breast. 2018 Aug;40:38-44
pubmed: 29677569
Breast. 2018 Feb;37:56-63
pubmed: 29100045